These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34916245)

  • 21. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
    Byun BH; Kim BI; Park SY; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH; Lim SM
    Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury.
    Hong YT; Veenith T; Dewar D; Outtrim JG; Mani V; Williams C; Pimlott S; Hutchinson PJ; Tavares A; Canales R; Mathis CA; Klunk WE; Aigbirhio FI; Coles JP; Baron JC; Pickard JD; Fryer TD; Stewart W; Menon DK
    JAMA Neurol; 2014 Jan; 71(1):23-31. PubMed ID: 24217171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
    Rinne JO; Wong DF; Wolk DA; Leinonen V; Arnold SE; Buckley C; Smith A; McLain R; Sherwin PF; Farrar G; Kailajärvi M; Grachev ID
    Acta Neuropathol; 2012 Dec; 124(6):833-45. PubMed ID: 23053137
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Moscoso A; Silva-Rodríguez J; Aldrey JM; Cortés J; Pías-Peleteiro JM; Ruibal Á; Aguiar P;
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1242-1253. PubMed ID: 34581847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.
    Nelissen N; Van Laere K; Thurfjell L; Owenius R; Vandenbulcke M; Koole M; Bormans G; Brooks DJ; Vandenberghe R
    J Nucl Med; 2009 Aug; 50(8):1251-9. PubMed ID: 19617318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal head-to-head comparison of
    Chen CD; McCullough A; Gordon B; Joseph-Mathurin N; Flores S; McKay NS; Hobbs DA; Hornbeck R; Fagan AM; Cruchaga C; Goate AM; Perrin RJ; Wang G; Li Y; Shi X; Xiong C; Pontecorvo MJ; Klein G; Su Y; Klunk WE; Jack C; Koeppe R; Snider BJ; Berman SB; Roberson ED; Brosch J; Surti G; Jiménez-Velázquez IZ; Galasko D; Honig LS; Brooks WS; Clarnette R; Wallon D; Dubois B; Pariente J; Pasquier F; Sanchez-Valle R; Shcherbinin S; Higgins I; Tunali I; Masters CL; van Dyck CH; Masellis M; Hsiung R; Gauthier S; Salloway S; Clifford DB; Mills S; Supnet-Bell C; McDade E; Bateman RJ; Benzinger TLS;
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2669-2682. PubMed ID: 37017737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis.
    Zeydan B; Lowe VJ; Reichard RR; Przybelski SA; Lesnick TG; Schwarz CG; Senjem ML; Gunter JL; Parisi JE; Machulda MM; Vemuri P; Mielke MM; Knopman DS; Petersen RC; Jack CR; Kantarci OH; Kantarci K
    Ann Neurol; 2020 Apr; 87(4):556-567. PubMed ID: 31970802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An exploratory efficacy study of the amyloid imaging agent [(18)F]flutemetamol in Japanese Subjects.
    Senda M; Yamamoto Y; Sasaki M; Yamane T; Brooks DJ; Farrar G; McParland B; Heurling K
    Ann Nucl Med; 2015 Jun; 29(5):391-9. PubMed ID: 25874747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced retention of Pittsburgh compound B in white matter lesions.
    Glodzik L; Rusinek H; Li J; Zhou C; Tsui W; Mosconi L; Li Y; Osorio R; Williams S; Randall C; Spector N; McHugh P; Murray J; Pirraglia E; Vallabhajolusa S; de Leon M
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):97-102. PubMed ID: 25331458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temporal and anatomical distribution of
    Yun T; Lee W; Kang JH; Yang MP; Kang BT
    BMC Vet Res; 2020 Jan; 16(1):17. PubMed ID: 31952531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment.
    Brown EE; Rashidi-Ranjbar N; Caravaggio F; Gerretsen P; Pollock BG; Mulsant BH; Rajji TK; Fischer CE; Flint A; Mah L; Herrmann N; Bowie CR; Voineskos AN; Graff-Guerrero A;
    J Neuroimaging; 2019 Nov; 29(6):721-729. PubMed ID: 31270885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers.
    Landau SM; Thomas BA; Thurfjell L; Schmidt M; Margolin R; Mintun M; Pontecorvo M; Baker SL; Jagust WJ;
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1398-407. PubMed ID: 24647577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale.
    Rowe CC; Jones G; Doré V; Pejoska S; Margison L; Mulligan RS; Chan JG; Young K; Villemagne VL
    J Nucl Med; 2016 Aug; 57(8):1233-7. PubMed ID: 26912446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Performance of 11C-Pittsburgh Compound B PET Binding Potential Images in the Detection of Amyloid Deposits on Equivocal Static Images.
    Hosokawa C; Ishii K; Kimura Y; Hyodo T; Hosono M; Sakaguchi K; Usami K; Shimamoto K; Yamazoe Y; Murakami T
    J Nucl Med; 2015 Dec; 56(12):1910-5. PubMed ID: 26359262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of T1-weighted/T2-weighted magnetic resonance ratio to elucidate changes due to amyloid β accumulation in cognitively normal subjects.
    Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Takahashi M; Nakagawara J; Iida H; Kishimoto T; Nagatsuka K
    Neuroimage Clin; 2017; 13():209-214. PubMed ID: 28003959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
    Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
    J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognitive aging in persons with minimal amyloid-β and white matter hyperintensities.
    Nebes RD; Snitz BE; Cohen AD; Aizenstein HJ; Saxton JA; Halligan EM; Mathis CA; Price JC; Kamboh MI; Weissfeld LA; Klunk WE
    Neuropsychologia; 2013 Sep; 51(11):2202-9. PubMed ID: 23911776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Visualization and Quantification of 3-Dimensional Stereotactic Surface Projections for 18F-Flutemetamol PET Using Variable Depth.
    Lilja J; Thurfjell L; Sörensen J
    J Nucl Med; 2016 Jul; 57(7):1078-83. PubMed ID: 26912445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between brain amyloid deposition and longitudinal changes of white matter hyperintensities.
    Cha WJ; Yi D; Ahn H; Byun MS; Chang YY; Choi JM; Kim K; Choi H; Jung G; Kang KM; Sohn CH; Lee YS; Kim YK; Lee DY
    Alzheimers Res Ther; 2024 Mar; 16(1):50. PubMed ID: 38454444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.